Holen Sie sich die Stockscreener-App
1.69
3.43%
-0.06
Handel nachbörslich:
1.69
Schlusskurs vom Vortag:
$1.75
Offen:
$1.75
24-Stunden-Volumen:
894.14K
Relative Volume:
1.07
Marktkapitalisierung:
$346.79M
Einnahmen:
$893.00K
Nettoeinkommen (Verlust:
$-151.61M
KGV:
-3.2803
EPS:
-0.5152
Netto-Cashflow:
$-135.31M
1W Leistung:
+9.03%
1M Leistung:
-12.89%
6M Leistung:
-20.28%
1J Leistung:
+137.83%
1-Tages-Spanne:
$1.675
$1.793
1-Wochen-Bereich:
$1.55
$1.806
52-Wochen-Spanne:
$0.54
$7.13
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.69 | 359.10M | 893.00K | -151.61M | -135.31M | -0.5152 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
Number of shareholders of ProKidney Corp. – NASDAQ:PROK - TradingView
PROK Technical Analysis | Trend, Signals & Chart Patterns | PROKIDNEY CORP (NASDAQ:PROK) - ChartMill
PROK Reiterated by HC Wainwright & Co. -- Price Target Maintained at $12 - GuruFocus
Analyst Maintains Sell on ProKidney Amid Single-Asset Risk and Long Path to 2028 BLA, Keeps $1 Price Target Below Market - TipRanks
ProKidney's first-quarter loss grows with increased operating expenses - Winston-Salem Journal
ProKidney Corp. (PROK) reports Q1 loss, tops revenue estimates - MSN
ProKidney Releases Q1 2026 Financial Results - AlphaStreet
Prokidney Corp reports results for the quarter ended March 31Earnings Summary - TradingView
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
ProKidney reports Q1 EPS (14c), consensus (14c) - TipRanks
ProKidney Highlights Progress in Pivotal Phase 3 CKD Trial - TipRanks
ProKidney Q1 loss widens as R&D spending rises - TradingView
PROKIDNEY CORP. 1Q 2026: Revenue $0.226M, EPS $(0.14) — 10-Q Summary - TradingView
PROK: Phase 3 trial enrollment on track; cash runway extends into mid-2027 amid rising R&D costs - TradingView
ProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial Results - Quiver Quantitative
PROK: Net loss widened to $42.6M in Q1 2026 as R&D spending rose for Phase 3 trials - TradingView
[8-K] PROKIDNEY CORP. Reports Material Event - Stock Titan
ProKidney (NASDAQ: PROK) Q1 2026 loss, R&D spend and cash runway to 2027 - Stock Titan
Kidney disease cell therapy ProKidney eyes key 2027 trial results - Stock Titan
BRIEF-ProKidney Q1 Operating Income USD -44.933 Million - TradingView
Press Release: ProKidney Reports First Quarter 2026 Financial Results and Business Highlights - Moomoo
TradingKey - TradingKey
PROKIDNEY CP (PROK) Eps Diluted (TTM) - Zacks Investment Research
ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
3 Promising Penny Stocks With Market Caps Up To $600M - Sahm
ProKidney (PROK) to Release Quarterly Earnings on Monday - MarketBeat
ProKidney approaches pivotal research, funding crossroads for drug therapy - Winston-Salem Journal
ProKidney Names Greg Madison as Chief Commercial Officer - HarianBasis.co
PROK - Finviz
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel - Insider Monkey
[SCHEDULE 13D/A] PROKIDNEY CORP. Amended Major Shareholder Report - Stock Titan
Control Empresarial converts 63.1M PROK (NASDAQ: PROK) Paired Interests into Class A shares - Stock Titan
Culleton - Winston-Salem Journal
9 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
MSN Money - MSN
ProKidney spikes after mid-stage trial data for lead asset - MSN
ProKidney's top executive gains nearly threefold hike in 2025 compensation - Winston-Salem Journal
ProKidney (PROK) Stock Live Trade (On the Radar) 2026-04-20Late Breakout - Cổng thông tin điện tử tỉnh Lào Cai
ProKidney (NASDAQ:PROK) Upgraded to Sell at Wall Street Zen - MarketBeat
ProKidney (NASDAQ:PROK) Stock Price Up 9%Should You Buy? - MarketBeat
Executive pay, governance on agenda at ProKidney (NASDAQ: PROK) vote - Stock Titan
ProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ProKidney (PROK) Stock: Trend Strength (Buying Pressure) 2026-04-15AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
ProKidney (NASDAQ:PROK) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Bull Run: Can ProKidney Corp continue delivering strong returns2026 Key Highlights & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Winners Losers: Is ProKidney Corp impacted by rising rates2026 Market Sentiment & Fast Entry High Yield Stock Tips - baoquankhu1.vn
High stakes: ProKidney pushes toward commercialization as cash dwindles, opportunity awaits - The Business Journals
Is ProKidney (PROK) Stock suitable for dividend investors | Price at $1.88, Up 1.35%Expert Momentum Signals - Xã Châu Thành
Analysis Recap: Will ProKidney Corp benefit from government policyQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Can ProKidney (PROK) Stock Reach New Highs | Price at $1.81, Down 4.74%Social Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai
April 2026 Penny Stock Highlights - Sahm
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):